Efficacy in Preventing Coronavirus Respiratory Infectious Diseases Recognized
Shinpoong Pharmaceutical announced on June 17 that the "pharmaceutical composition for the prevention or treatment of epidemic RNA virus infectious diseases" of 'Piramex (pyronaridine phosphate-artesunate)', which is approved as a malaria treatment, was granted a patent by the European Patent Office (EPO) on June 13.
The new use patent for Piramex covers not only artemisinin derivatives containing the main ingredients pyronaridine or artesunate, but also combination drugs formulated by combining these ingredients.
Shinpoong Pharmaceutical explained that the efficacy of Piramex has been recognized for a variety of coronavirus-related respiratory infectious diseases, including not only COVID-19, but also SARS (Severe Acute Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome).
In July 2023, Shinpoong Pharmaceutical registered the same composition patent for epidemic RNA virus infectious diseases in 17 countries belonging to the African Intellectual Property Organization (OAPI), and in March of this year, completed registration of the same composition patent in China for COVID-19 and MERS infections.
Yoo Jeman, CEO of Shinpoong Pharmaceutical, stated, "The novelty and inventiveness of Piramex for the treatment of coronavirus diseases have been recognized, establishing a foundation for global intellectual property rights. Based on the results of ongoing clinical trials, we will discuss the possibility of expanding indications with the Ministry of Food and Drug Safety to help patients suffering from coronavirus diseases, and we will do our utmost to make a substantial contribution to responding to global health crises through continued research."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
